The synthetic progestin, gestodene, affects functional biomarkers in neonatal rat osteoblasts through an estrogen receptor-related mechanism of action
- 22 March 2017
- journal article
- research article
- Published by Taylor & Francis Ltd in Endocrine Research
- Vol. 42 (4), 269-280
- https://doi.org/10.1080/07435800.2017.1294603
Abstract
Background: Clinical studies have shown that gestodene (GDN), a potent third-generation synthetic progestin, affects bone resorption. However, its mode of action in bone cells is not fully understood. The aim of this study was to establish whether GDN affects bone directly or through its bioconversion to other metabolites with different biological activities. Methods: In this study, we investigated the effects of GDN and its A-ring reduced metabolites on proliferation, differentiation, and mineralization of calvarial osteoblasts isolated from neonatal rat and their capacity to displace [3H]-E2 at ER binding sites. Results: In contrast to progesterone, gestodene did exert significant effects on osteoblast activities. The most striking finding was the observation that the A-ring reduced derivatives 3β,5α-tetrahydro-GDN and 3α,5α-tetrahydro-GDN, though to a lesser extent, had greater stimulatory effects on the osteoblast activity than those observed with GDN. The effects on osteoblast proliferation and differentiation induced by GDN-reduced derivatives were abolished by the antiestrogen ICI 182780, consistent with their binding affinities for the estrogen receptor. In addition, the presence of a 5α-reductase inhibitor or inhibitors of aldo-keto hydroxysteroid dehydrogenases abolished the GDN-induced enhancement of osteoblast differentiation. These results indicated that GDN is metabolized to the A-ring reduced metabolites with estrogen-like activities and through this mechanism, GDN may affect the osteoblast activity. Conclusion: Together, the data suggest that synthetic progestins derived from 19-nortestosterone such as GDN, have beneficial effects on bone due to their biotransformation into metabolites with intrinsic estrogenic activity.Keywords
Funding Information
- Departamento de BiologÃa de la Reproducción, INCMNSZ (001)
This publication has 38 references indexed in Scilit:
- Bioconversion of norethisterone, a progesterone receptor agonist into estrogen receptor agonists in osteoblastic cellsJournal of Endocrinology, 2008
- The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolitesJournal of Endocrinology, 2007
- The effects of progestins on bone density and bone metabolism in postmenopausal women: A randomized controlled trialAmerican Journal of Obstetrics and Gynecology, 2005
- Estrogen Receptor Isoform-Specific Induction of Progesterone Receptors in Human OsteoblastsJournal of Bone and Mineral Research, 2002
- Human cementum tumor cells have different features from human osteoblastic cells in vitroJournal of Periodontal Research, 1998
- Stimulatory effects of estrogen and progesterone on proliferation and differentiation of normal human osteoblast-like cells in vitroBiochemical and Biophysical Research Communications, 1992
- Efficacy of Low-Dose Oral Contraceptives Containing Levonorgestrel, Gestoden and Cyproterone AcetateGynecologic and Obstetric Investigation, 1987
- Effect of sex steroids on bone collagen synthesis in vitroCalcified Tissue International, 1978
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973